Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00147719 · ClinicalTrials.gov registry record · Phase 3

WelChol® With Metformin in Treating Patients With Type 2 Diabetes

A Phase 3 study of Type 2 Diabetes, sponsored by Daiichi Sankyo.

Completed
Registry status
Phase 3
Development phase
300
Enrollment target
20
Study locations

NCT00147719: Completed Phase 3 study of Type 2 Diabetes, sponsored by Daiichi Sankyo.

NCT00147719 is a Phase 3 study of Type 2 Diabetes that has completed, run by Daiichi Sankyo. The registered enrollment target is 300 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00147719, a Phase 3 study of Type 2 Diabetes, has completed, sponsored by Daiichi Sankyo.

COMPLETED
Registry status
Phase 3
Development phase
300 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the study is to see how safe and effective and tolerable the use of colesevelam hydrochloride is for type 2 diabetes when added to metformin alone or in combination with other anti-diabetic drugs.

Conditions Studied

Type 2 Diabetes

Interventions

  • DRUG Colesevelam hydrochloride

Study Locations (20)

California

  • - Beverly Hills
  • - Carmichael
  • - Fresno
  • - Irvine
  • - La Jolla
  • - Los Gatos
  • - San Diego
  • - Spring Valley
  • - West Hills

Florida

  • - Coco Beach
  • - Largo
  • - Miami
  • - Pembroke Pines
  • - West Palm Beach

Arkansas

  • CRO - Jonesboro

District of Columbia

  • - Washington D.C.

Georgia

  • - Atlanta

Indiana

  • - Evansville

Kentucky

  • - Louisville

Michigan

  • - Detroit

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2004-06
Est. Completion 2006-07
Phase Phase 3
Daiichi Sankyo

236 total trials

What the finished NCT00147719 record still lists

NCT00147719 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Colesevelam hydrochloride is the first listed.

NCT00147719 names 20 study sites across 8 states, led by California, Florida, Arkansas.

Frequently Asked Questions

What is clinical trial NCT00147719 about?

NCT00147719 is a clinical study titled "WelChol® With Metformin in Treating Patients With Type 2 Diabetes". The purpose of the study is to see how safe and effective and tolerable the use of colesevelam hydrochloride is for type 2 diabetes when added to metformin alone or in combination with other anti-diabetic drugs.

What is the current status of trial NCT00147719?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2004-06. Estimated completion is 2006-07.

What conditions does trial NCT00147719 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT00147719?

The interventions under investigation include: Colesevelam hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00147719?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00147719 being conducted?

This trial has 20 study locations across Arkansas, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00147719's enrollment target sits among peer trials

300 67th of 327 higher than 257 of 327 other Type 2 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00147719, the US trial registry maintained by the National Library of Medicine. NCT00147719 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.